Feed aggregator

Syndicate content

NIH rulemaking on transparency of clinical trials

Knowledge Ecology International - Tue, 25/11/2014 - 16:13

The NIH has a notice about a proposed rule that "clarifies and expands requirements for the submission of clinical trial registration and results information to the ClinicalTrials.gov database." Comments are due on or before February 19, 2015. We may ask the NIH to consider expanding the trials registry to include more information on the economics of clinical trials.

Here is a link to the Regulations.Gov docket for the proposed rule:

http://www.regulations.gov/#!documentDetail;D=NIH-2011-0003-0003

Categories: Front page

UACT sends letter to Tufts President, Chairman of Trustees, asking questions about R&D cost study

Knowledge Ecology International - Tue, 25/11/2014 - 16:09

On November 24, 2014. the Union for Affordable Cancer Treatment (UACT) sent a letter to Anthony P. Monaco, Office of the President, Tufts University, with copies to Michael Baenen, the Tufts Chief of Staff, and Peter Dolan, Chairman of the Board of Trustees for Tufts University, regarding the Tufts University press conference to announce an estimate of $2.6 billion as the R&D costs for new drugs.

read more

Categories: Front page

Film Screening: “The Internet´s own boy”

Trans Atlantic Consumer Dialogue - Tue, 25/11/2014 - 11:22

TACD is pleased to invite you to a film screening of “The Internet’s Own Boy: The Story of Aaron Swartz” on 1 December 2014 at 6:30 pm in the European Parliament.

Aaron Swartz represented the best and the brightest of a generation of young people who have grown up with the Internet. He was a brilliant programmer, writer and political activist who died tragically at a very young age. His legacy is specially relevant as we are considering new EU copyright legislation. Access to academic data, democratic control over information and freedom of speech were at the centre of his struggle. He sought change and was willing to disobey unjust laws to bring that change about. As you shall see in this documentary Aaron was very clear about his positions:

“Information is power but like all power, there are those who want to keep it for themselves. The world’s entire scientific and cultural heritage, published over centuries in books and journals, is increasingly being digitized and locked up by a handful of private corporations. There are those struggling to change this. The open access movement has fought valiantly to ensure that scientists do not sign their copyrights away but instead ensure their work is published on the Internet, under terms that allow anyone to access it.”

“There is no justice in following unjust laws. It’s time to come into the light and, in the grand tradition of civil disobedience, declare our opposition to this private theft of public culture. We need to take information, wherever it is stored, make our copies and share them with the world. We need to take stuff that’s out of copyright and add it to the archive. We need to buy secret databases and put them on the Web. We need to download scientific journals and upload them to file sharing networks. We need to fight for Guerilla Open Access.”

“With enough of us, around the world, we’ll not just send a strong message opposing the privatization of knowledge — we’ll make it a thing of the past. Will you join us?”

Should you require a badge for the European Parliament, please RSVP to dimi@wikimedia.be stating your full name, identity card/passport number, date of birth and nationality.

Details
Start:
December 1, 2014 6:30 pm
End:
December 1, 2014 8:30 pm
Venue
European Parliament
60 Rue Wiertz, Room ASP 3G2 Brussels, Belgium

+ Google Map

Categories: Front page

EU: RATIFY THE MARRAKESH TREATY! event on December 2nd

Trans Atlantic Consumer Dialogue - Tue, 25/11/2014 - 11:09

Ratify the Marrakesh Treaty
for the right to read of blind and other visually impaired persons

Sponsoring MEPs: Alessandra MORETTI (S&D, IT), Enrique CALVET CHAMBOM (ALDE, ES), Max ANDERSSON (Greens/EFA, SE)
Co-organisers:
Trans-Atlantic Consumer Dialogue (TACD)
European Blind Union (EBU)
World Blind Union (WBU)
Knowledge Ecology International (KEI) Europe
Date of event: 2 December 2014, 10:00-12:00
Location: European Parliament, room ASP A5G-1, Brussels

On June 28th, 2013 the Marrakesh Treaty to Facilitate Access to Published Works by Visually Impaired Persons and Persons with Print Disabilities was concluded in Morocco.

This international binding UN/WIPO treaty aims at ending the “book famine” that deprives 250 million people of access to culture and education. Visually impaired persons only have access to between 1 and 5% of the books published. The agreement focuses on copyright exceptions to facilitate the creation of accessible and affordable versions of books and other copyrighted works. It sets a norm for countries ratifying the Treaty to have a domestic copyright exception covering these activities, and allowing for the import and export of such material.

Objectives
The EU finally signed the Treaty in April 2014 and in October, 2014 the European Commission formally asked for authorization from the Council and the European Parliament to ratify the Treaty. Nevertheless, among a number of EU member states there is resistance against accepting EU competence over the ratification of the treaty despite the fact that both Commission and Council legal service opinions assert exclusive EU competence over this issue. If authorization of EU ratification is not accepted by EU member states, it will take many years before the Treaty is ratified and implemented.

Blind people, MEPs, the European Commission and other stakeholders will discuss the meaning of this landmark treaty for human rights and will urge swift ratification and implementation by the EU and its member states.

Programme
Welcoming remarks by Enrique CALVET CHAMBOM (ALDE, ES)
Why the EU should ratify the Marrakesh Treaty now and how to make it happen
Francisco Javier Martínez Calvo, Organización Nacional de Ciegos de España (ONCE)
Wolfgang Angermann, President, European Blind Union
Dan Pescod, International Campaigns Manager, Royal National Institute of the Blind, UK
Maria Martin-Prat, Head of Copyright Unit, European Commission

Closing remarks by Alessandra MORETTI (S&D, IT) & Max ANDERSSON (Greens/EFA, SE), JURI rapporteur on the Marrakesh Treaty
Should you require a badge for the EP, please RSVP to  HYPERLINK “mailto:ratify.tvinow@gmail.com” ratify.tvinow@gmail.com
stating your full name, identity card/passport number, date of birth and nationality.

Categories: Front page

“Can we afford our medicines?” Complete summary with document links

Trans Atlantic Consumer Dialogue - Mon, 24/11/2014 - 19:43

‘’Can we afford our medicines?
The access to medicines crunch in Europe”

European Parliament (room A3G-3), 12 November 2014, 12:30-15:00

Welcoming remarks by Kostas CHRYSOGONOS (GUE/NGL, EL)

Affordable access to medicines: the situation on the ground

Introduction by Beatriz BECERRA BASTERRECHEA (ALDE, ES) @beatrizbecerrab

Moderated by David Hammerstein @DaHammerstein, Senior policy advocate, TACD

  • François Berdougo @FBerdougo, Secretary General of the Harm Reduction Working Group of Médecins du Monde @MdM_France
  • Gonzalo Fanjul @GonzaloFanjul, Policy Director, IS Global Barcelona Institute for Global Health @ISGlobalorg
  • Rohit Malpani @MSF_access, Director, Access Campaign, Médecins Sans Frontières (MSF)

Q&A session

What can we do about the high cost of medicines?

Introduction by Michèle RIVASI (Greens/EFA, FR) @MicheleRivasi

Moderated by Ellen ‘t Hoen @ellenthoen, Medicines Law & Policy.

  • Jamie Love @jamie_love, Director, Knowledge Ecology International (KEI) & U.S. Chair of the Intellectual Property Committee, TACD 
  • Teresa Alves, International Policy Adviser, La Revue Prescrire,
  • Prof. dr. Graham Dukes, University of Oslo

Q&A session

The European Commission was represented by DG SANCO & DG Enterprise

Concluding remarks by Nessa CHILDERS (S&D, IE) @nchildersMEP

You can see & download speakers’ slide presentations at http://tacd-ip.org/archives/1238. The webstream of the whole event is here: http://greenmediabox.eu/en/ct/62-Can-we-afford-our-medicines- & at http://82.197.155.96/gmbox/39/src/20141112_medicines_or.mp4. Join the discussion on twitter using #a2mEurope. For any questions, email a2m.Europe@gmail.com.  Please see end of this report for additional sources of useful information.

Detailed summary

Kostas Chrysogonos (GUE/NGL, EL) welcomed everyone and explained that this event is necessary because the lack of access to medicines is a reality in many EU Member States today. Health services need to be reformed, he agreed, but not in a violent and irrational way. He continued by giving the example of the Greek situation with a number of citizens’ not receiving social security or access to healthcare, although they had paid their contribution to the social system for many years. It is not about excluded people or migrants, but people who used to work and are now unemployed. This is the case for many families in Greece which cannot be provided vaccination or access to treatments. The horizontal budget cuts excluded a big part of the population from health services, he explained, but this was also the case for other countries. There are cuts in the health service sector, and in the meantime, funds and resources are reduced drastically. Health products are no longer available as public goods but commercial products. Medical innovation is currently based on patent monopolies; a system no longer working. There were dis-functionalities before the crisis, administrative burden and reforms are necessary, he agreed, but the way they are doing them is wrong. This is all about cuts in spending. The reform should be the result of a social dialogue, not imposed by politicians, especially in countries under Troika supervision and not imposed by external actors. The subsidiarity principle should be taken into account. The needs of society and for adequate systems should correspond to modern needs without excluding citizens. He hoped that this meeting would allow for the undertaking of effective action.

Beatriz Becerra Basterrechea (ALDE, ES) began by explaining that she was a new MEP and did not know many things about medicines or research. She was not a doctor or a scientist, but she thought she was good with diagnosis. Health is not a luxury but a basic right, she stated. The question is about how to guarantee that right. Public funding must serve public interest. The crisis and imposed measures on budgets had dramatic consequences on access to medicines and should be the starting point for the rethinking of new models of public health pricing and medical innovation. It is not acceptable that millions of EU citizens are not receiving the highest quality life-saving medicines because governments cannot pay for the skyrocketing costs for the best treatments. The current model of medical innovation and pricing does not work. It has failed to promote real innovation and has become far too expensive for most of the world including many Member States, mentioning the case of hepatitis C treatments. The patent monopolies model was supposed to be an incentive for generating innovation but has turned out to be an obstacle. Its objective, of producing affordable useful products needed by societies, has failed. Public investment means 85 per cent of medical research must result in 85 per cent public return for public health instead of the privatization of knowledge by means of patent monopolies, she explained. Health innovation should develop products and services that are affordable and accessible. There is no doubt of the right of companies to have a profit, but life and death is a general interest issue and not just a business. New models are needed to break monopolies and push medicines towards real health needs and not just blockbuster profits.

Panel 1: Affordable access to medicines: the situation on the ground

David Hammerstein, senior policy advocate, TACD, introduced the panel and listed some of the keywords which might underpin this first session. Most notably, he drew attention to transparency, transparency of prices and transparency of clinical trials. How many times do we have to pay is also a question. Are public investment protected to give back public returnin form of public health and access to medicines? Another keyword is efficiency, with the question, are systems efficient, could they be more efficient by sharing knowledge, by sharing results and data? Hammerstein then raised the issue of unethical practices, competition issues touching upon the entry of generic onto the market and the relationship between doctors and pharmaceutical companies.

The monopoly issue is often linked to not fueling innovation but preventing it, he said. Monopoly is not a good word in this house, he added, and they have to be broken up. However, this has not been considered about the pharmaceutical sector in his opinion. Some people think there is a monopoly position in the production of R&D, with the marketing and selling of the products.

Hammerstein disagreed the EU lacked competence, and suggested it was about EU measures of fiscal austerity, of transparency, IPR policies, EU innovation and research policy and investment, non-discrimination and basic fundamental rights. No studies have been done on the health impact of the Greek budget cut measures, despite massive cuts. No provisions exist of how we are going to pay the price of best treatments for many medicines. There is no sharing of knowledge of Health Technology Assessments, he continued. No price caps are considered as the example of roaming in the EU. Solutions will come from civil society, experts and politicians, he added. Access to medicines and healthcare is the best policy. If it does not work for all, it is not working at all, he concluded.

François Berdougo, Secretary General of the Harm Reduction Working Group of Médecins du Monde began his presentation by giving a few highlights on the work of Médecins du Monde. Médecins du Monde documented the negative consequences of healthcare budget cuts in Greece on healthcare system and universal access to care. This includes an increase in users’ charges and the loss of healthcare coverage for approximately three million people. Médecins du Monde action worldwide focuses on programmes for drug users and their low access to life saving drugs. They defend the rights of drug users to access harm reduction services and show how the policies are feasible through programmes in different regions. Moreover, even in high income countries access to HCV treatments for injecting drug users remains low. Berdougo then went on to speak about the high level prices of HCV medicines, focusing on the example of Sofosbuvir. He explained that Sofosbuvir has strong therapeutic value and causes low side effects. However, in order to achieve universal access, affordable drugs are needed. Prices levels accepted in the US or considered in France are unbearable for many healthcare systems in a period of budget cuts. These price levels have consequences on access to drugs, he continued, leading to treatment rationing. He further illustrated his comments by comparing the necessary budget to treat all HCV patients with fibrosis stage F2 and above, being higher than the 2014 annual budget of Paris public hospitals. That situation has led to restricted recommendations of use by the High Authority for Health, because of the financial burden the French State would have to face, Berdougo said. In order to respond to risks of treatment rationing, Médecins du Monde built a coalition made of patient organisations, medical NGOs and found allies in healthcare professionals, economists and researchers. This coalition had been heard by the pricing commission, for the first time. It was the first time ever that civil society has been heard by this official state body. He reiterated that one of the key demands is for the French state to issue a compulsory-license for Sofosbuvir. Today, a debate exists in France on the issue of pricing criteria, new models of pharmaceutical innovation and research funding as a result, he said. He continued by mentioning the lessons learnt from the HIV issue and underlined that when there is competition from generics, prices can be driven down. He also noted the possibilities for governments to use the flexibilities offered by the TRIPS agreement, notably with regard to compulsory licenses or patent opposition. Compulsory licensing has been used by high income countries, he noted. He urged the institutions to push for a compulsory license, and if pricing negotiations between Gilead and the French government were to fail, for the government to use TRIPS flexibilities to achieve public health outcomes. They now promote a change of the legislation related to drug evaluation and pricing. He concluded by explaining that they will continue to promote a debate on medical innovation models driven by health needs and will try to put this issue higher up on the agenda. He stressed that implementing a compulsory license should be an option and not a dream.

Gonzalo Fanjul, Policy Director, IS Global Barcelona Institute for Global Health made a presentation on the impact of austerity policies on health and access to medicines. He began by mentioning a UNICEF campaign launched a couple of weeks ago on the impact of the crisis on children in the period 2008-2012 showing an increase in child poverty and capacity of families to cope with unexpected expenses. Fanjul explained the effect on mental health, nutrition patterns and lifestyle. Austerity seemed to be at the core of the problem, although it was not the only reason. He continued by explaining the two phases of fiscal response to the crisis. 2007-2009 showed an increase in social spending which reversed for the period 2010-2012 with the introduction of austerity. The impact has been extensive, diverse and likely to have long lasting effect on the right to health of EU citizens, he remarked. Health services were eroded with diverse intensity. It is still too early to speak about the broader consequences due to the lack of data, but Fanjul explained that they can already observe a huge increase of mental health disorders, as well as HIV and malaria outbreaks in Greece while waiting lists are expanding in many countries. There is also an increase in out of pocket expenses and restriction of coverage. Vulnerability appears to be a more difficult indicator to capture, however, indicators of fear of vulnerability have risen by 300 per cent in Spain due to the disappearance or weakening of traditional safety nets. Lessons learnt from the previous crises were of an increase of drug and alcohol abuse problems, psychological problems and long term effects of unhealthy behaviours in unemployed families. Coming back to the Spanish example, he raised the issue of nutrition patterns of children in school and malnutrition which were happening in critical periods of child development. The future impact on health capacity and productivity of the economy were easy to expect, he added. All of these factors raised the questions on how they were dealing with the crisis and the extent of how countries were following austerity policies. He then followed up on possible alternative reactions, comparing Greece and Spain with the Icelandic case. He further mentioned the possibilities raised by the WHO in times of austerity on health priorities and protection and vulnerability of groups, and on the debate with regard to efficiency and equity. Who is to be blamed, Germany, the Troika? Presenting a graph on the drivers of increasing inequality, he noted that the market was one of them, while transfers and taxes had also contributed to inequalities during the crisis.

Hammerstein suggested when people said that banks were too big to fail; he thought instead the emphasis should be that there are people who are too weak to fail.

Rohit Malpani, Director, Access Campaign, Médecins Sans Frontières (MSF) started with a presentation of MSF action worldwide and the access campaign launched in 2009. They observed that medicines are often unaffordable, not suited for conditions on the ground, or do not exist because the innovation system is not working in providing incentives. Lessons from the access campaign are that generic competition is a successful way to improve access to medicines, having led to a decrease of the cost of HIV medicines for example. Evidences are here showing that only generic competition leads to price reduction. This is also relevant for western countries, he added. The absence of generic competition shows unaffordable prices. The situation with new HIV/AIDS medicines which are under patent and monopolies make treatment unavailable for MSF and similiar organizations. There are therefore concerns about the economic sustainability of treatments, he continued, and not only concerning HIV/AIDS but for hepatitis C and other diseases.

The solution MSF promotes is the need for government to take action through TRIPS provisions. MSF is working in advocating for the use of these flexibilities. But EU countries and pharmaceutical companies are challenging the use of these safeguards and flexibilities in trade agreements. What the EU is pushing for instead is tiered pricing which, simply put, is offering different prices based on the perceived ability to pay of states. This is not a good strategy, he continued, as it allows charging whatever price companies wish. There are many problems: Industry is allowed to make decision about who pays what price, based on arbitrary criteria, such as GNI, not taking into account internal social differences. There is no sensitivity to economic and social factors and many patients are still left behind. Other concerns touch upon the lack of transparency of the prices paid in different jurisdictions. Therefore, governments cannot negotiate prices in an informed way. There is also no information, no transparency on research and development costs, he explained. Tiered pricing is arbitrary and irrational, he continued, and as well you often see countries paying different prices although ranking with the same GNI per capita.

The challenges today are what can be done to make changes. One way in the EU is the use of TRIPS flexibilities and price controls or to take other measures to increase transparency. They have to consider more deep changes to the current system not only looking at marginal changes but systemic changes.

Today’s innovation is based on patent monopolies. The cost of R&D is not linked to the price of the medicines, he said. Contesting the myth of the cost of R&D of medicines, he further referred to a statement made by GSK CEO on the cost of medicine development, being more about hundred million dollars than billions. MSF pleaded for developing a system that not only allowed for the development of affordable medicines but medicines that were needed. The crisis today is not only of access, he insisted, but of innovation. This is a challenge for the EU, giving the example of tuberculosis, antibiotics and Ebola. MSF asks for a system not driven by profit but health needs, new ways of creating incentives which delinks R&D costs from the end price. This could be through new models of R&D:

  • Innovation prizes

  • Patent pooling & equitable licensing

  • Open data

  • Collaborative data sharing.

MSF has developed a neglected diseases initiative pushing for the development of treatments for these diseases, making sure they are affordable. R&D has a cost, he agreed, and requires investment and risk. But the current system is not working for patients in the EU nor for the ones MSF is treating around the world. They hoped from today’s discussion to look at new models going beyond the patent system.

Hammerstein thanked MSF and said they were probably the ones that knew the situation on the ground the best. How can we ensure pharmaceutical R&D and social systems were health driven and not market driven, he asked.

Margrete Auken (Greens/EFA, DK) was shadow rapporteur on the clinical trials regulation and was calling for full transparency, she explained, with regard to the results and data of the trials once the marketing authorisation had been granted. There has been a big battle with the pharmaceutical industry over this. She also criticised the cost arguments. They have to be stronger and get rid of conflicts of interest of those prescribing medicines. Referring to Denmark, she said that the authorities do not call for a ban on conflict of interest but only declarations. They must be clearer that good administration means no conflict of interest.

Hara Georgiadou, Bridging Europe asked whether the 300 billion euros promised by President Juncker gave a place to health.

Marianella Kloka, Advocacy officer, Greek NGO PRAKSIS made a remark on transparency. They were at the beginning of the year invited by the WHO and the Greek ministry of health to contribute to the elaboration of health indicators to assess the outcomes of austerity measures and policy on health issues. They had no other communication since then even if promised with the results. Nevertheless, they have themselves started to monitor the situation, and have conducted research on beneficiaries of medicines for hepatitis C and vulnerable populations. Results show that visits to the doctor (for hepatitis C positive patients) decreased to 85 per cent from 2009 and onward, access to medicines (not innovative) was reduced to 65 per cent. They are talking about new innovative medicines today and they all want them, but she underscored what was happening with the current medicines.

Nikolas Tsemperlidis, representative from a Greek union of consumers raised the issue that access to medicines was connected to many parameters. This has to be connected to the social security systems, to income, competitiveness and entrepreneurship and people who serve medical societies. The representative then questioned the funding scheme of the European Medicines Agency, where 80 per cent is coming from the pharmaceutical industry while the US FDA model finds only 20 per cent. He pleaded for more in terms of transparency about what expert, what company, what financial interests, who is consulted. Moreover, approval should not only mention a majority in favour but declare who voted against. Finally, when it comes to temporary approvals, he asked, how are they given, whether there are limits. He concluded that the results of publicly-funded research should be available to the public for the common good.

Panayiotis Kouroumplis (Greek MP, leading opposition centre-left party SYRIZA) said that interests are important and influence decisions. The responsibility of civil society is important. If we decide to give up our rights to other people we will get the consequences. All today’s issues have to do with human dignity and access to medicines, he said. Nobody, without exception should depend on money to get access and stay alive. We need to find ways in order to react, and ways to develop another kind of thinking for all the people concerned by the issue, he concluded. He called for governments to consider issuing compulsory licenses.

Dr Eleni Alevritou, President, Greek Consumers Association EKPIZO said that her organisation is not exclusively dealing with medicines. Because of the situation in Greece they have decided to look at this area. She felt rather optimistic because of the presence of experts from different groups of the Parliament. The Parliament can today see excellent examples of the work of NGOs, she added.

Fanjul explained that in Spain as the result of fiscal constraint, they introduced prescription by active ingredients. This has been one of the main drivers of bringing down the pharmaceutical cost of the government back to the 2002 levels. What this means is that they should force the why not principle. In other words, when it comes to the issue of the use of compulsory licenses, governments should have to respond “why not?” at first and not “why?” If there are policy alternatives in these areas, why are they not implemented? That is what civil society should demand from governments.

Berdougo responded on transparency and conflict of interest. MDM made progress in France in highlighting conflicts of interests between patient groups & pharmaceutical companies, but at the moment they have to progress on transparency of financial relationship between health professionals and the pharmaceutical industry. They have to educate a lot of stakeholders about the R&D issue. A lot of physicians, politicians do not know about alternative models of R&D and research funding. This is important that politicians have these kinds of ideas as 10 per cent of MPs in France are actually health professionals. Nevertheless, they are brainwashed by pharma rhetoric. We have to change that, he concluded.

Malpani said that a lot of research is currently funded by public funds. Why are we not demanding more public investment? EU investment should be with a stringsattached in transparency, affordability and access. An important question is about what we are getting in return. A lot of public investment is made by Member States, and one of the most promising vaccines on Ebola was a decade ago handed over to the private sector. A substantial amount of money has been put into accelerating the development of three vaccines. What are we getting for the investment?, he asked. In terms of access on hepatitis C: new medicines can be affordable. The cost of producing them could be less than 200 dollars (as opposed to current 55.000$ price tag) with enough economies of scales in market places. We could be 18 months away from getting low cost hepatitis medicines on the market. “Why not?” he asked.

Panel 2: What can we do about the high cost of medicines?

Ellen’t Hoen moderator, Medicines Law and Policy said that she would like this panel to focus on solutions. She then invited Michele Rivasi (Greens/EFA, FR) to give an introduction.

Michele Rivasi (Greens/EFA, FR) explained the reasons why she was interested in the issue. As a biologist, her first approach to medicines issues came with the H1N1 pandemic when she criticised the alarmist decisions made by the WHO, as well as the conflicts of interest within the WHO and Member States pushing for the purchase of vaccines. At the time, there were differences of prices among countries and the result was that there had not been more death in countries having bought and used the vaccines than in others. She was also shadow rapporteur on the pharmacovigilance proposals, where the role of the EMA was looked at, and today thanks to the work of the European Parliament, experts’ declaration of interest has to be given. She further explained that she commissioned a study comparing prices of medicines in the EU, and the first results were that you find huge differences between countries (Italy, UK, France) due to different price strategy.

Rivasi then went on to speak about innovation, mentioning the case of Sofosbuvir and explaining that there is not so much innovation coming from big pharmaceutical companies nowadays, but that companies prefer buying innovative SMEs, increasing prices as each EU Member States is responsible for the price of medicines. This is very important because today it is about Sofosbuvir but there are also similar problems with breast cancer and hormonal cancer medicines. The problem can be seen in Greece where people cannot afford their medicines anymore. Tools are available, she explained and there must be an alternative to the patent system and exclusivity. She finally recalled that she posed the question in plenary and was answered that prices are a Member State’s competence. But each Member State has the possibility to make use of compulsory licensing and to open the license, asking other laboratories to develop the medicine and reduce its price. She is not against pharmaceutical laboratories, she explained, but there is an issue between public and private research. 1.8 billion euro is given by the EU to the Innovative Medicines Initiative (IMI) but without conditionality, she said. Public interest should come first, and she pleaded against the renationalisation of health. We have to act together to move forward, she concluded.

Jamie Love, Director, Executive Director, Knowledge Ecology International (KEI) & U.S. Chair of the Intellectual Property Committee, TACD made a presentation on implementing delinkage. He first agreed with previous speakers on the use of compulsory licenses. His presentation first explained the three main sources of funding for biomedical R&D, namely 1) grants from governments and charities; 2) profits from selling products protected by legal monopolies, the patent system is the most famous among them and 3) the drug tax credit offered by the US for the execution of clinical trials. Love continued by presenting figures (please consult respective slides) on the R&D investment from the private sector in comparison to global sales between 2004 and 2010, and illustrated his point with the case of cancer treatment R&D spending in Europe in 2009. After showing a graph on the relative spending on drugs and relative mortality rates for all cancers, showing a differential access and outcomes between countries with higher and lower income, he came with the idea of eliminating monopolies on cancer drugs and fund R&D with a combination of grants and three types of innovation prizes: End product prizes; Open source dividend; Milestone prizes. Furthermore, he developed on the EU example of an EU wide Cancer innovation fund and a plurilateral cancer innovation fund. He concluded on the role of Europe as supplier of innovation under the delinkage model, explaining that a greater reliance upon grants would first enhance the role of universities and SMEs in supplying innovation. Second the de-emphasis of marketing monopoly would create more competitive opportunities for SMEs in manufacturing and distributing. Last, new inventions can be patented, and patents can be fully exploited in foreign countries.

Teresa Alves, International Policy Adviser, La Revue Prescrire gave a presentation on “Stopping the spiral of exorbitant prices”. She began by introducing the publication Prescrire produced by medical professionals and financed from subscription only. They are a member of the international society of drugs bulletins and conduct drug reviews, looking at products and attributing ratings. More specifically, they assess, whether innovative medicines bring an advantage, harms reactions, efficacy and convenience for patients. They also make comparisons with existing products. Alves then went on to speak about results obtained between 2000 and 2013 to illustrate the crisis of innovation. The majority of new medicines add nothing new, are not responding to medical needs, according to their research. 14 per cent of them are even worse in safety and efficacy, bringing no advantage/benefit. She noted that over the past 13 years, 65% of all new medicines have had no real added therapeutic value. Less than 20 per cent of new medicines have some possible therapeutic added-value. These results are consistent with those of many other institutions and research centres.

Alves then argued that clinical research mainly funded by companies does not enough focus on unmet needs; aims to obtain a marketing authorisation without the need to prove therapeutic advance; and clinical trials tend to be used as marketing tools. At the same time, marketing approvals are given faster and faster; often based on weak evidence, with often insufficient post marketing risk minimisation measures and dangerous drugs being approved and subsequently withdrawn. She expressed serious concerns over the EMA’s adaptive licensing project which in her opinion can have dangerous implications for patients.

With regard to high medicine prices she explained that prices are often negotiated in opacity and not frequently based on real cost of production which remains unknown. There is also a disconnection between the drug price and its therapeutic value. She further explained that influential oncologists have described current prices of cancer medicine as “astronomical, unsustainable and even immoral”. These prices therefore put universal access and health protection systems at risk. Furthermore, money spent for expensive drugs with little added-value is money wasted for what is really needed by society.

Teresa Alves then illustrated her presentation with the case of Sofosbuvir treatment against hepatitis C. While Prescrire recognises that the new medicine offers an advantage, she noted the essential contribution of publicly funded research for its development. Furthermore, she compared estimated production cost of 100 USD per patient to the 84.000 USD cost per patient per treatment. She said that the clinical trials were just enough to obtain the marketing authorisation and that there is little data about long term adverse drug reactions and drug interactions. The company justifications for this high price are about expected savings in medication use, transplants and hospitalisation, she explained. However, Alves highlighted that this forecast has been contested and that these savings would be obtained in 20 years if severely-ill patients were to be treated. She further noted that Sofosbuvir is under a voluntary licence in 91 countries but stated that this might simply be a window-dressing exercise since numerous other countries are excluded. Finally, Alves explained the high price Gilead paid to buy Pharmasset, the developer of the drug, in 2011 for 11bn dollars, and the need to recoup investment. She emphasized that Gilead paid 139$ per stock in 2011 for Pharmasset, while Pharmasset’s value in 2005 was only 5$ per stock.

Alves presentation concluded with suggestions about what is needed. First is to rethink the R&D system, with more research into unmet medical needs, more comparative clinical trials to demonstrate therapeutic advance compared to existing medicines, more publicly funded research and to set prices that reward real innovation. This would also mean to refuse exorbitant prices, use flexibilities such as compulsory licences, and demand evidence of therapeutic advance as criteria in marketing authorization. Finally, that would also mean opening the “black box”, with transparency and access to clinical, regulatory and pricing data, allow independent analysis and information sharing, encourage public scrutiny and identify real innovation.

Prof. dr. Graham Dukes, University of Oslo said that there is waste of money that could be used for good purposes. High medicine prices are demanded and accepted because of the widely propagated belief that the industry is committed to high research costs and that research record is proven successful. However, when in the US, the Security and Exchange Commission examined drug companies data, it found out that on average, only some 13 per cent of company revenues were spent on research while 48 per cent went on administration, marketing and profits. He continued by giving the example of an American firm that argued before a Dutch court that the cost of cancer drugs reflected research expenditure, while it actually happened that the costs had been supported by US public funds. The Dutch court accepted the claim that it would be seriously disadvantageous if a generic company was allowed to produce the same drug at a lower price. The legend that drugs cost a lot to develop is, amongst others, propagated by the Tufts Center for the Study of Drug Development which has the purpose of providing the drug industry with arguments to justify prices when dealing with the authorities. It has produced highly biased reports over the years. In his view, this Centre should have been closed down ages ago by an honest industry. The best and most sensible and successful critical approach of pricing is the one existing in Australia, Prof. Dukes continued. Producers were obliged to price the products at the same level of that of existing generic or other drugs long on the market, unless be proven that the products was better, safer or had other advantages. It brought down and kept low prices, but had to be abandoned following elections when an industry-sympathetic lobby acquired power. Using American data in matters of drug pricing and costs can be useful but it would be better to have EU data, he explained. We could, in a number of countries, secure reliable data of the cost to develop drugs and how companies are spending their money. More transparency is needed on the way money is used and how it could be improved. Prof. Dukes then underlined the possible merits of pooled procurement, a system that could have two or three countries working together.

Prof. Dukes then raised the issue of uncritical prescribing, with some doctors over-prescribing due to the pressure of commercials or patients, who believe that they have to come back from the doctor with a prescription. The commercial person is of no need, a financial burden on the community, he said. The result of its work is in over prescribing and waste. There is a solution tried on small scales, the employment of persons sent out by authorities or impartial bodies. They are credible and successful. Commercial detailing would be prohibited and then taken over by employing people providing unbiased, reliable information. Doctors do need information like this. At least, this could provide a mean of keeping the doctors properly informed. The approach is popular among doctors and highly appreciated. As for the patients’ pressure, there is no quick solution but it is a matter of education. But this belief needs to be progressively eradicated.

Ellen ‘t Hoen asked about better transparency of pricing in the EU and the role of the European Commission. Considering the suggestion made this afternoon regarding new models for R&D, would it be possible with the resources of the Commission spent on the pharmaceutical industry to pilot these new models and try them?, she asked. Moreover, she asked what role the Commission can play in ensuring transparency in drug pricing.

Thomas Heynisch Deputy Head of Unit, Food and Healthcare Industries, Biotechnology, DG ENTR said that on drug pricing, article 168 of the Treaty gave clear responsibility to Member States when it comes to management of health care. This is the basic line. Recalling the question on transparency, he explained that the remit of the Commission services was limited. There is only one available instrument and that is the Transparency Directive. The Commission appreciated the support from the Parliament when trying to amend the Directive, however it is currently stuck in the Council. Generics can play a major role in reducing cost, everybody agrees, and the Commission called for speedy pricing and reimbursement decision for generics, but with no endorsement from Member States so far. Everybody agrees too that the linkage between intellectual property and pricing and reimbursement decisions are not conducive to early access. This was also in the Transparency Directive. Heynisch continued on the issue of biosimilars, which can play a major role in driving down treatment costs. The Commission is trying to promote the acceptance of biosimilars as a way to have high quality medicines available in Member States while respecting Member States role and the roles of the value chain including prescribers. He noted that the last presentation referred to the question whether prescribers are informed about the properties of biosimilars. With regard to orphan drugs that tend to be costly, the role of Member States is again clear. DG ENTR launched a working group to promote cooperation among Member States, but noted that Member States are equally defending their turfs. One of the concrete outcomes was that the Commission managed to convince several member states to engage in further activity. It fosters the cooperation among member states.

On non-availability of medicinal products in Member States, this requires a detailed analysis. They had a working group and after having conducted a survey with competent authorities, it appears that is not the costly products that seem to be in needs, the problem coming from the availability of low cost products.

On adaptive licencing, there are concerns, but the phenomenon to push for off-label use comes because of cost containment. Adaptive licensing if done properly requires the involvement of the authorities. On the Innovative Medicines Initiative, he explained that the funds are not available to big pharmaceutical companies but SMEs and academia. He stressed that public money is not going to big pharma.

He agreed that they should have a closer look at alternative models and they want to have a comprehensive approach. He encouraged interested parties to ask the Commission to have a closer look at these models. Recently, they asked participants in the Rome meeting to come with concrete priority topics-deadline is the end of this month. The Commission is open to suggestion on areas where the Commission should be more active.

Nessa Childers (S&D, IE) summed up the meeting as she had to join the plenary session. She began by saying that the situation in Ireland wasn’t fine, especially in the case of health services. Access to healthcare and pharmaceuticals was not good in the first place even before the crisis she explained. There are long waiting lists in public health services for diagnoses. Access to healthcare is a public good, she stated, this is also a human right. On the Member State competence claim, she responded that in a country like Greece, it is no question that this is a breach of rights set in the Treaty. Breach of human rights is not a competence of Member States, it has to do with the whole of Europe. Mr Berdougo explained that the wide coalition built achieved results. She then explained that one thing worked in politics, it is fear of politicians that they would lose their seat. Civil society also has to expose the power of lobbyists. She called for a wide coalition in the health area, so that governments would begin to reinvest money, which had been taken out of the system. She concluded by insisting on the question of human rights and the breach of the Charter of Fundamental Rights in Greece when it came to access to public health services.

Dirk Van Den Steen, Team leader Healthcare systems unit, DG SANCO explained that the Commission did understand that there is a problem, this is why the Commission put out a Communication on Health Systems where medicines are singled out as a specific area where there are concerns. This is Member States’ territory so the Commission could support Member States that proposed initiatives such as the one from France. He further indicated that the Commission supported the work of the Council reflection process on responsible health system and that the health programme included an action on reference pricing. This is one way of helping the debate. They had similar initiatives in the new health programme looking at pricing models. The Commission looked forward to the outcome of the discussion in the working party on pharmaceuticals and medical devices on innovation for the benefit of patients that should see council conclusions in December 2014.

Merel Philippart,Universities Allied for Essential Medicines (UAEM) asked why society is dependent on pharma companies, while most innovative medicines are a result of publicly funded research. She said that society pays twice both for the research but also for the high prices. Why can’t states fund their own production? she asked.

David Preece, European Association of Hospital Pharmacists (EAHP) said that the problem of shortages was affecting access in hospitals for new innovative as well as generic medicines covering a wide area. They would issue a report in the coming week.

A representative from the European Haemophilia Consortium asked the European Commission representatives whether the legal instrument of joint procurement had already been used and were there plans to use it for hepatitis C treatment or other diseases.

Evangelia Kikeleki, member of the EESC also member of a consumer organisation spoke on behalf of the consumers against the transfer of responsibilities for medical devices from DG SANCO to DG ENTR. Juncker said that health was not for sale and could not belong to DG ENTR. She also asked about the risks brought about by the current discussion on TTIP.

A representative of the European association of pharmacists commented on the absence of debate on the impact of TTIP on access to medicines.

A representative from the European Platform for Patients’ Organisations, Science & Industry asked the question whether there are enough patients involved. He said he had not heard anything on bringing orphan drugs to the patients as well as on the EU/US agreement (TTIP).

Prof. Dukes replied on own R&D that it has been done to a small extent, mentioning centres in San Francisco and Strasbourg working on drugs set aside by big companies. These groups are promising. Other proposals have been made to establish further groups, he indicated. It can be done but so far only on small scale.

Alves on TTIP referred to a paper published by a coalition of NGOs. There are a lot of strings attached, putting access to medicines and health at risk. She agreed that TTIP is a clear and present danger.

Love thought that TTIP was a threat to health in Europe. What is needed is to demand for negotiations not to be secret while it was not for a lot of lobbyists in the US. On patient groups, he explained that in the US, the typical situation was that patient groups were focusing on reimbursement policies and to make sure people were covered, but not challenging prices directly. He also mentioned that in many cases patient groups are heavily influenced by big pharmaceuticals. He criticized the Commission for not stepping up the fight against the high prices of innovative drugs. The EU has an interest to protect itself from high prices of cancer drugs, he added.

Heynisch assured everyone that the European Commission never had the intention to jeopardise access to medicines in Europe. Certain requests with regard to including pricing and reimbursement issues in the TTIP negotiations are not endorsed by the Commission as they had to have a closer look at the different healthcare systems on both sides of the Atlantic. The incompatible approach to coverage and financing does not make a convincing argument in engaging in discussions on this within TTIP because it might end up with a one-way street.

Additional sources of information:

  • TACD resolution on access to medicines (A2M), November 2014

http://tacd.org/new-resolution-on-access-to-medicines/

  • TACD, HAI Policy Paper “Time for the EU to lead on innovation: EU policy opportunities in biomedical innovation and the promotion of public knowledge goods”

http://haieurope.org/wp-content/uploads/2012/04/HAI-Europe_TACD-EU-Innovation-Paper.pdf

  • Update: TTIP Civil society response paper to Big Pharma wish list

http://commonsnetwork.eu/new-coat-ttip-civil-society-response-paper-to-big-pharma-wish-list/

  • HAI Europe Recommendations: Keys to improving access to, and the rational use and

good governance of, medicines in Europe

http://haieurope.org/wp-content/uploads/2014/10/HAI-Europe-recommendations-to-improve-A2M.pdf

  • Trading Away Access to Medicines (Revisited) – New report from HAI Europe and Oxfam

http://haieurope.org/wp-content/uploads/2014/09/Trading-Away-Access-to-Medicines-Revisited.pdf

  • Europe for access to medicines & public health care-10 commitments for the new European Parliament, November 2014

http://saludporderecho.org/wp-content/uploads/2014/11/DECALOG-eng.pdf

 

Categories: Front page

The Winning Bet

Knowledge Ecology International - Tue, 18/11/2014 - 20:44

Leading up to the release of Professor Joe DiMasi's latest study of the cost of drug development, KEI offered $50 to the individual who could most accurately predict the new cost for drug R&D.

We received 26 guesses, ranging from $1.157 billion to $5 billion.

Joel Lexchin's estimate ($2.47 billion) was the closest to DiMasi's number ($2.558 billion). It was also the 5th largest estimate.

A complete list of submissions is below.

Name & Guess
Charles Clift - 1.157 billion
Nicole H - 1.2 billion
Ronald Rader - 1.55 billion
Wouter Deelder - 1.655 billion

read more

Categories: Front page

KEI comment on the new Tufts Study on Drug Development Costs

Knowledge Ecology International - Tue, 18/11/2014 - 16:39

The Tuft Center for Study of Drug Development (CSDD) has just concluded a press conference, and issued a press release about their new study of drug development costs. The key number is $2.558 billion.

read more

Categories: Front page

What to look for in the new Tufts study on drug development costs. 10 issues.

Knowledge Ecology International - Mon, 17/11/2014 - 19:19

When the new Tufts study on the costs of R&D for development of a new drug is released Tuesday at 10AM, here are 10 things to look for:

read more

Categories: Front page

Research note on oncology drugs, including trial size and orphan drug status

Knowledge Ecology International - Mon, 17/11/2014 - 17:53

We will be sharing some data on 2005 to 2014 oncology approvals, including the size of the trials cited in the medical review, and the orphan status.

The spreadsheet we are working on updating is published here:

read more

Categories: Front page

KEI Research Note: Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results

Knowledge Ecology International - Mon, 17/11/2014 - 17:50

A copy of the research note is also available here as a pdf file: http://keionline.org/sites/default/files/kei-rn-2014-3.pdf

KEI Research Note 2014:3

Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results

Elizabeth Rajasingh
November 17, 2014

Introduction

read more

Categories: Front page

Presentations at event “Can we afford our medicines?” 12-11-14

Trans Atlantic Consumer Dialogue - Fri, 14/11/2014 - 09:46

Here you can find the slide presentations given at the event “Can we afford our medicines?” that took place on November 12th, 2014 at the European Parliament.  The webstream of the whole event is here: http://greenmediabox.eu/en/ct/62-Can-we-afford-our-medicines- . Thanks to all who made the event a big success and we hope it will be a turning point in the fight for universal access to quality health treatments in Europe.

MDM Intervention FBerdougo @EP Medicines

Rohit Malpani, Access Campaign MSF

James Love, Implementing Delinkage, Cancer prize fundEU Parliament 12 November 2014 TA

Gonzalo Fanjul, IS Global

version finale Teresa Alves

 

Categories: Front page

Ten bullet points on the upside down world of pharmaceuticals, prices and access

Trans Atlantic Consumer Dialogue - Thu, 13/11/2014 - 08:55

CAN WE AFFORD OUR MEDICINES?

Notes from introduction to “Can we afford our medicines?” event in EP, 12-11-2014

1. Transparency: Today there is no transparency on prices EU states pay for medicines(taxpayers often don´t know what their state health service is paying for each medicine), no transparency on scientific research/clinical trials or safety and efficacy, nor on R and D costs nor is there clear traceability of the costs of producing a new medicine, We´re in the dark, middle ages. Doctors don´t know, Patients don´t know, Politicians don´t know, Taxpayers don´t know.
2. How many times do we pay? Three is a massive privatization of public investment in research. “I already paid for this drug!” is a reality. Where is the public return on investment in research if there are there no strings attached to our investment as far as IPR, affordability or knowledge exploitaiton? We often re-buy taxpayer research at an astronomical cost and end up paying for a medicine 3,4 or 5 times (taxes, co-payment, medical insurance, tax evasion of pharmaceutical companies, paywalls around public research results, ..)
3. Public Good, not just a commodity: Health is a public good, health knowledge is a public good, part of the global commons. Is access to medicines mainly a competitive business issue or a public health question?
4. Is the present system efficient? Marketing costs dwarf research, most new drugs have little therapeutic value (me toos, evergreening), cost of not sharing data of clinical trials, overprescription and underprescription are two sides of same coin. Safety and efficacy of medicines are often hidden. There is great over-lap and waste in research, marketing and deception.
5. Corruption or unethical practices are massive: Pay to delay practices to prevent generics on market cost public health systmes billions. Massive perks for doctors, unethical lobbying by paid pseudo patient groups, massive tax evasion by big pharma (where is the so called “trickle-down” benefit for all?) and thousands of lobbyists in Brussels that work to place pharma profits ahead of affodable public healh needs.
6. Monopoly and Malice: Patent monopolies do not fuel innovation but often prevent it- thickets, scientific enclosure, fear of sharing, scientific manipulation. In Energy and Telecom: measures for structural unbundling of dominant positions have been proposed or taken in market in favor of consumers, competition and lower prices; but EU patients have no such advantage. There are clear dominant positions in the pharma market: Direct or indirect control of R and D, production, IPR portfolios, marketing and sales- end up moulding and manipulating of whole cycle.
7. It is the EU´s competence!: It is often said that health and pharmaceutical pricing are not direct EU competences but indirectly they are. Fiscal austerity, Transparency, IPR policy, EU innovation and research, non-discrimination..
8. Evidence based EU policy: No econometric studies on different innovation models No impact evaluation of EU promoted austerity cuts in health budgets, No provision of how Europeans will pay skyrocketing medicines expenditures of an aging population and more expensive drugs, No EU project to share health technology assesments. No price caps considered, No socially responsible licensing proposals for EU research..
9. De-linkage and open source dividend: Separate R and D costs from final costs of medicines through prizes, patent pools and open medical research. Fund an open source dividend to incentivize sharing of scientific research. Promote socially responsible licensing when public money is involved.
10. If it is not good for the majority, it is not good. Marginal costs of producing medicines are very low, universal access is possible if there is political will to break monopolies. Access is the best policy: If it doesn´t work for the majority, it simply doesn´t work.

Categories: Front page

The problem of unaffordable medicines and the need for health-driven innovation are not on EU agenda

Trans Atlantic Consumer Dialogue - Tue, 11/11/2014 - 16:59

Due to the high cost of medicines, millions of citizens of EU member states cannot receive proper medical treatment for a number of very serious illnesses. Practically half of the EU population is excluded from the most effective treatments for cancer, Hepatitis C and other life-saving medicines simply because they (nor their public health systems) cannot pay for them. Despite this fact, there is no clear political reaction to this situation, not even an organized debate nor a coherent search for policy proposals, studies or pilot programmes. Surprisingly, this situation is rarely considered a political and moral scandal. Health inequality is not usually considered any less acceptable than general social inequality. Unfortunately, EU supported austerity measures that have forced health-care budget cuts have made this bad situation even worse.

After many meetings this week with the health attachés from a number of important EU member states that are members of the Council´s working groups on pharmaceuticals and public health, I have reached the depressing conclusion that to date initiatives on the price of medicines and new health-driven innovation models are practically non-existent in the institutional sphere. None of the major EU member states recall ever having discussed any innovation or pricing alternatives to the Pharma patent monopoly driven model. This is in a context in which a number of these same countries admit that their states either cannot afford to buy some of the best life-saving treatments or they are forced to ration them to a small percentage of the patients who need them.

It is surprising that while there are legal EU price caps on telephone roaming rates and data roaming, no one proposes controlling prices of life-saving medicine prices. And it is not just a question of competences but of political will to place health first ahead of the dominant “growth, jobs, innovation” rant.

While there have been some political and parliamentary rumblings that complain about the high price of some medicines, namely the Hepatitis C cure Sovaldi, there are no concrete, viable proposals on the official political table that could bring down the price of life-saving medicines and/or promote new biomedical innovation models driven by real health needs. On the contrary, there are a number of serious proposals on the EU short-term agenda (medicine price Directive, TTIP, greater IPR protection, “personalized, innovative medicines”..) that could even make it more difficult in the future to bring down the price of medicines or introduce health-driven innovation models.

“Access to medicines” is usually understood by the European Commission, EU member states and other policy makers as meaning making new products “available for patients”, getting them “on the market” or “over the regulatory hurdles”, never about being affordable. Aside from some occasional rhetorical, lip-service about patients needs, pharmaceuticals is seen primarily and secondarily as issue of “growth, jobs and industrial innovation” rather that a public good. No one at all contests the constant official EU equivalency of stronger, longer patent protection and data exclusivity with “innovative medicines” nor objects at all to the coupling of high medicine prices with the high research costs of a new generation of “personalized medicine”. There is no consideration of protecting the “public return” of massive public investments in biomedical R and D nor preventing the privatization of public health-related knowledge. The pharma mantra is so pervasive that often European Commission officials from DG Enterprise, DG Research and DG Sanco are “more catholic than the Pope” in defending industry orthodoxy on IPR, transparency and high prices. A rather minor example: the EU policy to promote “open data” research with EU finding has just excluded any research related to health because it would be “too controversial”. The ideological, regulatory and legislative capture by the pharmaceutical industry is almost complete in Brussels with very few exceptions such as the inconclusive, partial victories such as the Regulation on clinical trial transparency.

A few issues now on the table in the EU Council and in the European Commission:

  1. Joint Procurement: France has proposed pooled procurement solely to purchase Hepatitis C treatment Sovaldi. It is not at all clear if this will ever materialize. A number of countries have shown an interest in this initiative but there is a reluctance to share information and many countries such as Spain or France itself have gone on to negotiate secret agreements with the company Giliad on their own. The success of this initiative is very doubtful because of the lack of openness.

  1. Transparency of prices: The Directive on medicine prices (now being considered by the Council) is all about the Pharma industry having access to government procurement processes and health technology actions in each EU member state so the Pharma industry can be able to take action against the lowering of prices on “innovative medicines”. It is not at all about the publication of the real prices each member state pays Pharma for medicines. These procurement prices are kept secret. As a result, the pharmaceutical industry knows perfectly well the prices and conditions negotiated by each European state while each government negotiating prices is totally in the dark about the prices paid by neighboring European countries. By “divide and conquer” the industry is at a great advantage in negotiating prices.

  1. TTIP and pharmaceuticals: like everywhere else, the pharma wish-list – all oriented to market-driven innovation, high prices and higher IPR protection is very present at the negotiating table for both EU and US negotiators.

Categories: Front page

Former WTO Director-General, Pascal Lamy, mooted to chair Global Fund's Equitable Access Initiative

Knowledge Ecology International - Tue, 11/11/2014 - 12:01

On 14 March 2014, KEI published "Resurrecting the Ghost of Høsbjør Past: Global Fund seeks to establish global framework on tiered pricing enforced by WTO rules" in which we provided an analysis of the Global Fund's plans to create a global framework for tiered pricing enforced by the rules of the World Trade Organization (WTO).

read more

Categories: Front page

WIPO patent committee (SCP21): Intervention of KEI on Patents and Health

Knowledge Ecology International - Wed, 05/11/2014 - 10:36

The following intervention on patents and health was delivered by KEI during the 21st session on WIPO's Standing Committee on the Law of Patents (SCP). Part 1 was delivered on 4 November 2014 during discussions of the Feasibility Study on the Disclosure of International Nonproprietary Names (INN) in Patent Applications and/or Patents. Part 2 was delivered on 5 November 2014 during general discussions on patents and health.

Statement of Knowledge Ecology International (KEI)

Item 7: Patents and health

Part 1

read more

Categories: Front page

WIPO patent committee (SCP21): Intervention of Pakistan on Patents and Health

Knowledge Ecology International - Wed, 05/11/2014 - 10:08

On Wednesday, 5 November 2014, Pakistan delivered the following intervention on patents and health.

Agenda 7 Statement on patents and health

1. General statement

Mr. Chair,

I will make this statement in national capacity,

read more

Categories: Front page

WIPO Standing Committee on the Law of Patents (SCP 21): Intervention of Pakistan on Opposition Systems

Knowledge Ecology International - Tue, 04/11/2014 - 19:29

On Tuesday, 5 November 2014, Pakistan delivered the following intervention on opposition systems.

Mr. Chairman,

The agenda item on quality of patents also include another item on "opposition systems" which was not discussed by the Committee. I want to make a small statement on opposition systems.

read more

Categories: Front page

WIPO patent committee (SCP21) to discuss International Nonproprietary Names and Exceptions and Limitations to Patent Rights

Knowledge Ecology International - Mon, 03/11/2014 - 11:55

In the words of the International Bureau of the World Intellectual Property Organization (WIPO), the WIPO Standing Committee on the Law of Patents (SCP) was created,

created in 1998 to serve as a forum to discuss issues, facilitate coordination and provide guidance concerning the progressive international development of patent law.

read more

Categories: Front page

WTO TRIPS Council (October 2014): Statement of India on the Review of the Paragraph 6 system (compulsory licensing for export)

Knowledge Ecology International - Wed, 29/10/2014 - 17:49

On 28 October 2014, India delivered the following intervention at the WTO TRIPS Council's annual review of the Paragraph 6 system (designed to facilitate compulsory licensing for export of pharmaceuticals).

In particular, India noted that

read more

Categories: Front page